MoonLake Immunotherapeutics is facing a class action lawsuit that could shake its standing in the pharmaceutical world. Shareholders have taken legal action against the company, alleging securities fraud that spans from March 10, 2024, to September 29, 2025. The core of the lawsuit revolves around MoonLake’s sole drug candidate, SLK, and its purported advantages over BIMZELX.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The complaint claims that MoonLake misled investors by asserting that SLK’s unique Nanobody structure would offer superior clinical benefits compared to BIMZELX’s traditional monoclonal structure. However, it is alleged that both drugs target the same inflammatory cytokines, IL-17A and IL-17F, and that SLK’s supposed enhanced tissue penetration does not translate into actual clinical efficacy. These allegations suggest that MoonLake’s optimistic statements about SLK’s superiority lacked a reasonable basis.
For those who invested in MoonLake during the specified period and suffered financial losses, there is an opportunity to seek recovery. Shareholders are encouraged to visit the provided link to understand their rights and explore the possibility of recouping their losses. Participation in the lawsuit comes with no cost or obligation.
Renowned for its strength in securities litigation, Levi & Korsinsky LLP is committed to securing justice for all plaintiffs. With a track record of securing hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S., Levi & Korsinsky is well-equipped to handle this high-stakes case.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171